Cargando…

Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer

BACKGROUND AND PURPOSE: Leptomeningeal metastases (LM) is the end-event of lung cancer and the prognosis is dismal. Few studies explored the prognostic performance of systematic immunological levels in lung cancer patients with LM. Our study aimed to explore the possible relationship between the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ye, Duan, Ping, He, Lang, Li, Qing, Chen, Yueyun, Wang, Peipei, Fu, Yang, Liu, Ting, Ding, Zhenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934871/
https://www.ncbi.nlm.nih.gov/pubmed/35321403
http://dx.doi.org/10.2147/CMAR.S347323
_version_ 1784671924840824832
author Hong, Ye
Duan, Ping
He, Lang
Li, Qing
Chen, Yueyun
Wang, Peipei
Fu, Yang
Liu, Ting
Ding, Zhenyu
author_facet Hong, Ye
Duan, Ping
He, Lang
Li, Qing
Chen, Yueyun
Wang, Peipei
Fu, Yang
Liu, Ting
Ding, Zhenyu
author_sort Hong, Ye
collection PubMed
description BACKGROUND AND PURPOSE: Leptomeningeal metastases (LM) is the end-event of lung cancer and the prognosis is dismal. Few studies explored the prognostic performance of systematic immunological levels in lung cancer patients with LM. Our study aimed to explore the possible relationship between the prognosis of LM and systematic immunological level and other clinical characteristics. METHODS: This retrospective, multi-institutional, observational study was conducted in 4 tertiary centers in China. Patients were screened from January 2009 to May 2019. Patients with radiographically or histologically confirmed LM were enrolled. The data of systematic immunological level and other clinical characteristics of each patient were extracted and statistically analyzed to establish a prognostic model based on statistical analysis results. The predictive accuracy and discriminative capability of the model were evaluated by the calibration curve and concordance index (C-index). RESULTS: A total of 109 patients were enrolled in the study. Patients with adenocarcinoma, tumors harboring EGFR mutation, at their age of 50–59, with either bone, brain, or lung metastases, were enriched in this cohort. The median overall survival (OS) was 20.4 months (95% CI: 15.2–25.6). Cox univariate and multivariate analysis revealed better PS (0–1), no distant lymph nodes metastasis (DLNM), simultaneous diagnosis of lung cancer and leptomeningeal metastasis (SDLL), and lower neutrophil to lymphocyte ratio (NLR), were associated with better OS. Based on these independent prognostic variables, a prognostic nomogram model with a C-index for OS prediction of 0.71, was constructed. The actual probability of survival at 1-, 2- and 3-year showed good concordance with the prediction curve of our nomogram. CONCLUSION: The systematic immunological level was an independent prognostic factor of lung cancer patients with LM. The prognostic model based on statistical analysis had a good ability to predict the OS of patients.
format Online
Article
Text
id pubmed-8934871
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89348712022-03-22 Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer Hong, Ye Duan, Ping He, Lang Li, Qing Chen, Yueyun Wang, Peipei Fu, Yang Liu, Ting Ding, Zhenyu Cancer Manag Res Original Research BACKGROUND AND PURPOSE: Leptomeningeal metastases (LM) is the end-event of lung cancer and the prognosis is dismal. Few studies explored the prognostic performance of systematic immunological levels in lung cancer patients with LM. Our study aimed to explore the possible relationship between the prognosis of LM and systematic immunological level and other clinical characteristics. METHODS: This retrospective, multi-institutional, observational study was conducted in 4 tertiary centers in China. Patients were screened from January 2009 to May 2019. Patients with radiographically or histologically confirmed LM were enrolled. The data of systematic immunological level and other clinical characteristics of each patient were extracted and statistically analyzed to establish a prognostic model based on statistical analysis results. The predictive accuracy and discriminative capability of the model were evaluated by the calibration curve and concordance index (C-index). RESULTS: A total of 109 patients were enrolled in the study. Patients with adenocarcinoma, tumors harboring EGFR mutation, at their age of 50–59, with either bone, brain, or lung metastases, were enriched in this cohort. The median overall survival (OS) was 20.4 months (95% CI: 15.2–25.6). Cox univariate and multivariate analysis revealed better PS (0–1), no distant lymph nodes metastasis (DLNM), simultaneous diagnosis of lung cancer and leptomeningeal metastasis (SDLL), and lower neutrophil to lymphocyte ratio (NLR), were associated with better OS. Based on these independent prognostic variables, a prognostic nomogram model with a C-index for OS prediction of 0.71, was constructed. The actual probability of survival at 1-, 2- and 3-year showed good concordance with the prediction curve of our nomogram. CONCLUSION: The systematic immunological level was an independent prognostic factor of lung cancer patients with LM. The prognostic model based on statistical analysis had a good ability to predict the OS of patients. Dove 2022-03-15 /pmc/articles/PMC8934871/ /pubmed/35321403 http://dx.doi.org/10.2147/CMAR.S347323 Text en © 2022 Hong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hong, Ye
Duan, Ping
He, Lang
Li, Qing
Chen, Yueyun
Wang, Peipei
Fu, Yang
Liu, Ting
Ding, Zhenyu
Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
title Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
title_full Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
title_fullStr Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
title_full_unstemmed Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
title_short Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
title_sort systematic immunological level determined the prognosis of leptomeningeal metastasis in lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934871/
https://www.ncbi.nlm.nih.gov/pubmed/35321403
http://dx.doi.org/10.2147/CMAR.S347323
work_keys_str_mv AT hongye systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT duanping systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT helang systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT liqing systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT chenyueyun systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT wangpeipei systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT fuyang systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT liuting systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer
AT dingzhenyu systematicimmunologicalleveldeterminedtheprognosisofleptomeningealmetastasisinlungcancer